In stock COA
NOVALYTE
LABS
LABS
NOVALYTELABS
CJC-1295 (with DAC)5mg · RESEARCH USE ONLY
CJC-1295 (with DAC)5mg · RESEARCH USE ONLY
Low stock COA DOCUMENT SLOT
Growth ResearchCJC-1295 (with DAC)
Modified GHRH analog with Drug Affinity Complex (DAC), studied for sustained growth hormone release in research models.
Research catalogueLaboratory-use positioning
Batch documentationBatch certificate supplied with order
Order trackingFrom payment to dispatch
Product information
CompoundCJC-1295 (with DAC)
Presentation5mg vial
CategoryGrowth Research
AvailabilityLow stock
Batch COACertificate supplied with order
€99.00
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use.
Overview
CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH, amino acids 1-29) modified with a Drug Affinity Complex. The DAC extension allows covalent binding to serum albumin after injection, significantly extending its half-life from minutes to approximately 6-8 days in research models. This prolonged activity profile enables sustained elevation of growth hormone and IGF-1 levels, making it a widely studied compound in endocrinology and growth factor research.
Mechanism of Action
CJC-1295 binds to GHRH receptors on anterior pituitary somatotroph cells, stimulating adenylate cyclase and increasing intracellular cAMP levels. This triggers the release of stored growth hormone in a pulsatile pattern that preserves physiological secretion rhythms. The DAC moiety forms a stable bond with circulating albumin via reactive lysine residues, shielding the peptide from enzymatic degradation (DPP-IV) and renal clearance, thereby extending its plasma residence time.
Research Applications
- Growth hormone axis research and GH secretion kinetics
- IGF-1 pathway signalling studies
- Sustained-release peptide pharmacokinetics
- Body composition research in preclinical models
- Pituitary function and somatotroph cell biology